|
|
Post by sla55 on Oct 27, 2017 8:36:44 GMT -5
cnafinance.com/mannkind-corporation-mnkd-stock-edging-up-ahead-of-earnings/16936MannKind Corporation (NASDAQ: MNKD) is having a relatively strong start to the trading session this morning after the company announced that it will be releasing its earnings report relatively soon. Of course, this led to excitement among investors who are sending the stock upward. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:00), MNKD is trading at $3.63 per share after a gain of $0.11 per share or 3.12% thus far today. MNKD Edges Up On Coming Earnings As mentioned above, MannKind Corporation is having a relatively strong start to the trading session this morning after the company announced that it would be releasing its financial results for the third quarter relatively soon. In a press release, offered early this morning, the company announced that it will be releasing its third quarter financial results on Tuesday, November 7th, and it will be hosting a conference call in order to discuss these results as well as other developments. MNKD will be holding the call at 5:00 PM Eastern Time on November 7th. During the conference call, MNKD CEO, Michael Castagna, Chief Financial Officer, Steven Binder, and Chief Commercial Officer, Pat McCauley, will all be presenting data and opinions with regard to the third quarter and forward looking projections. If you'd like to participate in the conference call, you can do so by dialing (888) 771-4371 or (847) 585-4405. When dialing in, please use the participant passcode, 44096374. The call will also be streamed online at www.mannkindcorp.com. What We'll Be Watching For Ahead Moving forward, the CNA Finance team will continue to keep a close eye on MNKD. In particular, we're interested in following the earnings call and excited to see the results. On top of earnings, we're following Afrezza sales incredibly closely considering the recent label change, funding, and more. Nonetheless, we'll continue to follow the story closely and bring the news to you as it breaks!
|
|
|
|
Post by itellthefuture777 on Oct 27, 2017 9:14:40 GMT -5
My guess is Merger or we get to hear about Receptor Life Science or How Many Merck laid off 1800 sales Employees took Mike up on the job offers..hmm
|
|
|
|
Post by dreamboatcruise on Oct 27, 2017 12:08:04 GMT -5
My guess is Merger or we get to hear about Receptor Life Science or How Many Merck laid off 1800 sales Employees took Mike up on the job offers..hmm Well we did hear about RLS already. Hopefully if he talks about it this time it will be some real news like time line and amount of an upcoming milestone payment. I'm not yet taking a hit off this RLS tease, despite peer pressure to do so. A merger of course isn't going to happen anytime soon now that we aren't at near term risk of bankruptcy. |
|
|
|
Post by itellthefuture777 on Oct 27, 2017 12:20:01 GMT -5
My guess is Merger or we get to hear about Receptor Life Science or How Many Merck laid off 1800 sales Employees took Mike up on the job offers..hmm Well we did hear about RLS already. Hopefully if he talks about it this time it will be some real news like time line and amount of an upcoming milestone payment. I'm not yet taking a hit off this RLS tease, despite peer pressure to do so. A merger of course isn't going to happen anytime soon now that we aren't at near term risk of bankruptcy. Merck is probably thinking...better to buy MNKD while they have the asset of sales reps to offer..verses wasting the asset..losing them to Mannkind..then buying them..or partnering..but Merck already blinked..day after Mike offered to hire Merck sales staff..Merck all the sudden is in aquisition mode..What is Merck thinking? They are thinking they lay off their skilled sales staff..and lose them yo another bidder for Mannkind...forever..thing is..Mannkind can hire immediately..so now Merck needs to move quick..so does Sanofi..and Lilly..or they lose Mannkind..the golden egg..forever..hmm |
|
|
|
Post by liane on Oct 27, 2017 12:30:14 GMT -5
|
|
|
|
Post by dreamboatcruise on Oct 27, 2017 12:30:18 GMT -5
Well we did hear about RLS already. Hopefully if he talks about it this time it will be some real news like time line and amount of an upcoming milestone payment. I'm not yet taking a hit off this RLS tease, despite peer pressure to do so. A merger of course isn't going to happen anytime soon now that we aren't at near term risk of bankruptcy. Merck is probably thinking...better to buy MNKD while they have the asset of sales reps to offer..verses wasting the asset..losing them to Mannkind..then buying them..or partnering..but Merck already blinked..day after Mike offered to hire Merck sales staff..Merck all the sudden is in aquisition mode..What is Merck thinking? Theybare thunking they lay off their skilled sales staff..and lose them yo another bidder for Mannkind...forever..thing is..Mannkind can hire immediately..so now Merck needs to move quick..so does Sanofi..and Lilly..or they lose Mannkind..the golden egg..forever..hmm The asset they just paid severance to in order to get rid of. Would make no sense. |
|
|
|
Post by itellthefuture777 on Oct 27, 2017 12:32:31 GMT -5
Merck is probably thinking...better to buy MNKD while they have the asset of sales reps to offer..verses wasting the asset..losing them to Mannkind..then buying them..or partnering..but Merck already blinked..day after Mike offered to hire Merck sales staff..Merck all the sudden is in aquisition mode..What is Merck thinking? Theybare thunking they lay off their skilled sales staff..and lose them yo another bidder for Mannkind...forever..thing is..Mannkind can hire immediately..so now Merck needs to move quick..so does Sanofi..and Lilly..or they lose Mannkind..the golden egg..forever..hmm The asset they just paid severance to in order to get rid of. Would make no sense. Pennys for dollars.. |
|
|
|
Post by twibs66 on Oct 27, 2017 12:51:12 GMT -5
everyone that comments on this board is all opinion ? whats yer point |
|
|
|
Post by dreamboatcruise on Oct 27, 2017 14:07:26 GMT -5
everyone that comments on this board is all opinion ? whats yer point Much that is posted is based on something other than rank speculation. I certainly appreciate posters that try to indicate what they are basing their comments on... I try to do that. Itell's post wasn't particularly bad in this respect, though obviously he has no info about how probable any thought is in someone else's mind. It would have been a little better if he'd started with "I wish Merck were thinking" because it would seem this is purely wishful thinking. |
|
|
|
Post by joeypotsandpans on Oct 27, 2017 14:57:11 GMT -5
everyone that comments on this board is all opinion ? whats yer point Much that is posted is based on something other than rank speculation. I certainly appreciate posters that try to indicate what they are basing their comments on... I try to do that. Itell's post wasn't particularly bad in this respect, though obviously he has no info about how probable any thought is in someone else's mind. It would have been a little better if he'd started with "I wish Merck were thinking" because it would seem this is purely wishful thinking. It's my opinion that Merck is not in the picture to get involved with Afrezza, they are heavily reliant on Januvia/Janumet and it would be reminiscent of the SNY situation. I would personally prefer to see a leading biotech that believes more in innovative product like AMGN or GILD which are flush with cash and looking to replace their products that are going off patent or slowing sales with long term innovative technology like technosphere in areas that do not compete with their current pipelines. When we get the scripts traction that we believe will come within the next 6 mos. and the PAH treatment further along we may get more interest but right now its keeping our eye on prize and getting sales going again IMO. Once we have some proof (sales) in the pudding then I would love to see Mike play poker with AMGN/GILD competing with one another, here's to dreaming and with that here is my song for the weekend, have a great one!!: A little bit of Ozzy, he even mentions mankind  : www.youtube.com/watch?v=LCCiwPEdEpg |
|
|
|
Post by mnholdem on Oct 27, 2017 16:22:53 GMT -5
Ordinary I would agree, but Merck has been facing headwinds as European bio similar are cutting into its revenue. I read an article recently where the author stated, "Historically, patent expiration causes the vast majority of brand-name drug sales to shift to competitors, however, it's anyone's guess exactly how quickly that will happen at Merck. Merck's fast-growing drugs provide it with some insulation, and if the company secures FDA approval of MK-1293, a bio similar to the $6 billion plus per year insulin Lantus, then it may be in even better shape to handle the hit to sales caused by expiring patents."
That got me to thinking that if Merck is planning to market a potential blockbuster basal insulin, why not consider a potential blockbuster prandial insulin -Afrezza?
It may be reaching, but I'm not ready to totally dismiss the idea of a collaboration or M&A. Having Merck become a parent corporation to MannKind presents some exciting capabilities, PAH to name just one.
|
|
|
|
Post by itellthefuture777 on Oct 27, 2017 20:33:39 GMT -5
Just to be clear..everything is speculation 100%.. always..and I am long MNKD..If it reads like there is more to it..there is not..it is just thenway my mind works..connecting dots..fragments..trying to make sense of what is happening...thus..speculating..If I knew for sure..I would sell everything I own..including the dog and buy more..but..it is okay to be optimistic..and to speculate which is all that ever occurs here as far as I know..a space to say what we think..link what we find..on the net..if possible..but..I soeculate that the first partner would be Sanofi...using my logic process..I doubt they are done with Mnkd..and doubt they are happy if mnkd gets Merck sales force because I see Sanofi as very territorial..but it could easily be no one..or someone else..know one knows..except my dog..but she won't tell me!
|
|
|
|
Post by sportsrancho on Oct 27, 2017 20:41:09 GMT -5
Just to be clear..everything is speculation 100%.. always..and I am long MNKD..If it reads like there is more to it..there is not..it is just thenway my mind works..connecting dots..fragments..trying to make sense of what is happening...thus..speculating..If I knew for sure..I would sell everything I own..including the dog and buy more..but..it is okay to be optimistic..and to speculate which is all that ever occurs here as far as I know..a space to say what we think..link what we find..on the net..if possible..but..I soeculate that the first partner would be Sanofi...using my logic process..I doubt they are done with Mnkd..and doubt they are happy if mnkd gets Merck sales force because I see Sanofi as very territorial..but it could easily be no one..or someone else..know one knows..except my dog..but she won't tell me! Great post:-) Agree |
|
|
|
Post by nylefty on Oct 27, 2017 21:28:12 GMT -5
Just to be clear..everything is speculation 100%.. always..and I am long MNKD..If it reads like there is more to it..there is not..it is just thenway my mind works..connecting dots..fragments..trying to make sense of what is happening...thus..speculating..If I knew for sure..I would sell everything I own..including the dog and buy more..but..it is okay to be optimistic..and to speculate which is all that ever occurs here as far as I know..a space to say what we think..link what we find..on the net..if possible..but..I soeculate that the first partner would be Sanofi...using my logic process..I doubt they are done with Mnkd..and doubt they are happy if mnkd gets Merck sales force because I see Sanofi as very territorial..but it could easily be no one..or someone else..know one knows..except my dog..but she won't tell me! Please don't sell the dog! |
|
|
|
Post by mydogskip on Oct 28, 2017 7:24:59 GMT -5
Ordinary I would agree, but Merck has been facing headwinds as European bio similar are cutting into its revenue. I read an article recently where the author stated, "Historically, patent expiration causes the vast majority of brand-name drug sales to shift to competitors, however, it's anyone's guess exactly how quickly that will happen at Merck. Merck's fast-growing drugs provide it with some insulation, and if the company secures FDA approval of MK-1293, a bio similar to the $6 billion plus per year insulin Lantus, then it may be in even better shape to handle the hit to sales caused by expiring patents." That got me to thinking that if Merck is planning to market a potential blockbuster basal insulin, why not consider a potential blockbuster prandial insulin -Afrezza? It may be reaching, but I'm not ready to totally dismiss the idea of a collaboration or M&A. Having Merck become a parent corporation to MannKind presents some exciting capabilities, PAH to name just one. Until Mannkind can show Afrezza can sell, no BP is going to touch it. The opportunity to have done so is when Sanofi walked away and no deals were had. Mannkind has a lousy record of making deals (or bogus deals). As I have stated before, it doesn't matter if you lengthened the financial runway when your airplane doesn't have enough fuel to reach liftoff and you have one missing wheel. |
|
: 
